+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Hematological Malignancies Market by Disease Type (Leukemia, Lymphoma, Multiple Myeloma), Treatment Type (Chemotherapy, Immunotherapy, Stem Cell Transplantation), Therapy Class, Line Of Therapy, End User, Distribution Channel, Patient Age Group - Global Forecast 2025-2030- Product Image
Hematological Malignancies Market by Disease Type (Leukemia, Lymphoma, Multiple Myeloma), Treatment Type (Chemotherapy, Immunotherapy, Stem Cell Transplantation), Therapy Class, Line Of Therapy, End User, Distribution Channel, Patient Age Group - Global Forecast 2025-2030- Product Image
Sale

Hematological Malignancies Market by Disease Type (Leukemia, Lymphoma, Multiple Myeloma), Treatment Type (Chemotherapy, Immunotherapy, Stem Cell Transplantation), Therapy Class, Line Of Therapy, End User, Distribution Channel, Patient Age Group - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5887514
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The hematological malignancies market is rapidly transforming as precision medicine, cellular therapies, and digital technologies drive significant advances. Senior decision-makers now face a complex landscape of evolving scientific breakthroughs, regulatory shifts, and dynamic global market forces that impact both patient care and strategic growth opportunities.

Market Snapshot: Hematological Malignancies Market Growth and Performance

The Hematological Malignancies Market grew from USD 16.84 billion in 2024 to USD 18.58 billion in 2025. It is expected to continue growing at a CAGR of 9.95%, reaching USD 29.76 billion by 2030. The market’s upward trajectory is fueled by the rising adoption of targeted therapeutics, cellular engineering advances, and increased demand for personalized cancer care. Innovators, providers, and payers are increasingly focused on strategies that balance access with economic sustainability, making this segment a focal point for R&D investment and cross-sector collaboration.

Scope & Segmentation of the Hematological Malignancies Market

The report comprehensively covers core segments and regional perspectives, capturing the latest in technology, delivery models, and patient demographics.

  • Disease Types: Leukemia, Lymphoma (including Hodgkin and non-Hodgkin types), Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Neoplasms
  • Treatment Types: Chemotherapy, Immunotherapy (CAR-T, checkpoint inhibitors), Stem Cell Transplantation, Targeted Therapy (immunomodulators, monoclonal antibodies, proteasome inhibitors, tyrosine kinase inhibitors)
  • Therapy Classes: Cellular therapies (CAR-T, dendritic cell vaccines), Immunomodulatory drugs, Monoclonal antibodies, Proteasome inhibitors, Small molecule inhibitors
  • Lines of Therapy: First-line, Maintenance, Second-line, Third-line and beyond
  • End Users: Ambulatory care centers, Hospitals, Research institutes, Specialty clinics
  • Distribution Channels: Direct purchase, Hospital pharmacies, Online pharmacies, Retail pharmacies
  • Patient Age Groups: Adult, Geriatric, Pediatric
  • Regions: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, and others), Asia-Pacific (China, India, Japan, Australia, South Korea, and others)
  • Leading Companies: Bristol-Myers Squibb Company, Johnson & Johnson, AbbVie Inc., F. Hoffmann-La Roche AG, Novartis AG, Gilead Sciences, Pfizer Inc., Amgen Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited

Key Takeaways for Senior Decision-Makers

  • Precision therapies and advanced diagnostic platforms are shaping more individualized, effective blood cancer management, improving clinical pathways and patient stratification.
  • Supply chain optimization and regional production hubs are growing priorities as market participants confront economic and regulatory complexities, especially in the face of emerging tariffs and reimbursement pressures.
  • Collaborative partnerships between biotech innovators and established pharma companies are accelerating late-stage asset development, sharing risk, and extending commercial reach.
  • Segmentation by disease type, treatment modality, and patient cohort underscores critical differences in infrastructure needs, access, and care delivery models.
  • Adoption rates for novel therapies and the speed of regulatory approvals vary significantly by region, influenced by government budgets, reimbursement systems, and clinical trial capacity.

Tariff Impact and Supply Chain Dynamics

New US import tariffs targeting pharmaceuticals and diagnostic equipment in 2025 have introduced cost challenges for manufacturers and suppliers of hematological cancer therapies. Companies are actively reassessing sourcing strategies, exploring nearshoring and diversified vendor portfolios to reduce risk and maintain supply continuity. Delayed equipment deliveries and increased expenses impact launch timelines and production capacity, requiring careful alignment of procurement, pricing, and reimbursement models. The burden is especially acute for smaller biotech firms, which may be less able to withstand sudden cost escalations, potentially affecting ongoing clinical research and product availability.

Methodology & Data Sources

This analysis uses a mixed-methods approach, integrating quantitative market intelligence with qualitative expert consultations. Primary data were obtained from discussions with oncologists, bioprocess engineers, regulatory authorities, and CMO executives. Rigorous secondary research incorporated peer-reviewed journals, clinical trial databases, regulatory filings, and industry white papers. Triangulation techniques validated consistency and enriched scenario analysis on regulatory and market policy shifts.

Why This Report Matters: Actionable Insights for Decision-Makers

  • Supports evidence-based strategy and pipeline prioritization by integrating granular segmentation analysis, technology trends, and stakeholder perspectives.
  • Enables resilience planning through clear assessment of tariff impacts, regional adoption patterns, and up-to-date supply chain risks.
  • Drives organizational alignment with patient-centric care models and ESG principles by providing benchmarks on innovation, sustainability, and regulatory advocacy.

Conclusion

The Hematological Malignancies Market is navigating significant transformation, with precision therapies, novel technologies, and global policy changes setting new benchmarks for care and competition. Forward-thinking leaders will benefit from harnessing these insights to achieve resilient, patient-focused growth amidst ongoing industry change.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rapid adoption of bispecific T-cell engagers driving novel immunotherapy options for relapsed multiple myeloma
5.2. Emerging role of CAR-NK cell therapies in reducing graft versus host disease for leukemia patients
5.3. Integration of circulating tumor DNA assays for early detection and monitoring of treatment response in lymphoma
5.4. Advancements in antibody-drug conjugate delivery systems enhancing targeted therapy specificity in B-cell malignancies
5.5. Shift towards outpatient administration of novel oral kinase inhibitors improving quality of life for chronic myeloid leukemia patients
5.6. Increasing investment in real-world evidence studies to support market access and reimbursement for rare hematologic cancer drugs
5.7. Expansion of telemedicine and remote monitoring solutions in managing treatment adherence for hematological malignancies
5.8. Growing emphasis on neoantigen vaccine development for personalized immunotherapy in acute myeloid leukemia treatment
5.9. Regulatory acceleration programs facilitating faster approval pathways for breakthrough therapies in hematologic cancers
5.10. Advances in epigenetic modulator combinations offering novel therapeutic strategies in refractory multiple myeloma management
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Hematological Malignancies Market, by Disease Type
8.1. Introduction
8.2. Leukemia
8.2.1. Acute Lymphoblastic Leukemia
8.2.2. Acute Myeloid Leukemia
8.2.3. Chronic Lymphocytic Leukemia
8.2.4. Chronic Myeloid Leukemia
8.3. Lymphoma
8.3.1. Hodgkin Lymphoma
8.3.1.1. Classical
8.3.1.2. Nodular Lymphocyte-Predominant
8.3.2. Non-Hodgkin Lymphoma
8.3.2.1. B-Cell
8.3.2.2. T-Cell
8.4. Multiple Myeloma
8.5. Myelodysplastic Syndromes
8.5.1. Refractory Anemia
8.5.2. Refractory Anemia With Excess Blasts
8.5.3. Refractory Anemia With Ring Sideroblasts
8.5.4. Refractory Cytopenia With Multilineage Dysplasia
8.6. Myeloproliferative Neoplasms
8.6.1. Essential Thrombocythemia
8.6.2. Myelofibrosis
8.6.3. Polycythemia Vera
9. Hematological Malignancies Market, by Treatment Type
9.1. Introduction
9.2. Chemotherapy
9.3. Immunotherapy
9.3.1. CAR-T Cell Therapy
9.3.2. Checkpoint Inhibitors
9.4. Stem Cell Transplantation
9.4.1. Allogeneic
9.4.2. Autologous
9.5. Targeted Therapy
9.5.1. Immunomodulators
9.5.1.1. Lenalidomide
9.5.1.2. Thalidomide
9.5.2. Monoclonal Antibodies
9.5.2.1. Anti-CD20
9.5.2.2. Anti-CD38
9.5.3. Proteasome Inhibitors
9.5.3.1. Bortezomib
9.5.3.2. Carfilzomib
9.5.4. Tyrosine Kinase Inhibitors
9.5.4.1. BCR-ABL Inhibitors
9.5.4.2. BTK Inhibitors
10. Hematological Malignancies Market, by Therapy Class
10.1. Introduction
10.2. Cellular Therapies
10.2.1. CAR-T Cell Therapy
10.2.2. Dendritic Cell Vaccines
10.3. Immunomodulatory Drugs
10.3.1. Pomalidomide
10.3.2. Thalidomide
10.4. Monoclonal Antibodies
10.4.1. Anti-CD20
10.4.2. Anti-CD38
10.5. Proteasome Inhibitors
10.5.1. Bortezomib
10.5.2. Carfilzomib
10.6. Small Molecule Inhibitors
10.6.1. Tyrosine Kinase Inhibitors
10.6.2. Venetoclax
11. Hematological Malignancies Market, by Line Of Therapy
11.1. Introduction
11.2. First-Line
11.3. Maintenance Therapy
11.4. Second-Line
11.5. Third-Line And Beyond
12. Hematological Malignancies Market, by End User
12.1. Introduction
12.2. Ambulatory Care Centers
12.3. Hospitals
12.4. Research Institutes
12.5. Specialty Clinics
13. Hematological Malignancies Market, by Distribution Channel
13.1. Introduction
13.2. Direct Purchase
13.3. Hospital Pharmacies
13.4. Online Pharmacies
13.5. Retail Pharmacies
14. Hematological Malignancies Market, by Patient Age Group
14.1. Introduction
14.2. Adult
14.3. Geriatric
14.4. Pediatric
15. Americas Hematological Malignancies Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Hematological Malignancies Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Hematological Malignancies Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Bristol-Myers Squibb Company
18.3.2. Johnson & Johnson
18.3.3. AbbVie Inc.
18.3.4. F. Hoffmann-La Roche AG
18.3.5. Novartis AG
18.3.6. Gilead Sciences, Inc.
18.3.7. Pfizer Inc.
18.3.8. Amgen Inc.
18.3.9. Sanofi S.A.
18.3.10. Takeda Pharmaceutical Company Limited
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. HEMATOLOGICAL MALIGNANCIES MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THERAPY CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THERAPY CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 18. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. HEMATOLOGICAL MALIGNANCIES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. HEMATOLOGICAL MALIGNANCIES MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. HEMATOLOGICAL MALIGNANCIES MARKET: RESEARCHAI
FIGURE 30. HEMATOLOGICAL MALIGNANCIES MARKET: RESEARCHSTATISTICS
FIGURE 31. HEMATOLOGICAL MALIGNANCIES MARKET: RESEARCHCONTACTS
FIGURE 32. HEMATOLOGICAL MALIGNANCIES MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. HEMATOLOGICAL MALIGNANCIES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CLASSICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CLASSICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY NODULAR LYMPHOCYTE-PREDOMINANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY NODULAR LYMPHOCYTE-PREDOMINANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HODGKIN LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY B-CELL, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY B-CELL, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY T-CELL, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY T-CELL, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REFRACTORY ANEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REFRACTORY ANEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REFRACTORY ANEMIA WITH EXCESS BLASTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REFRACTORY ANEMIA WITH EXCESS BLASTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REFRACTORY ANEMIA WITH RING SIDEROBLASTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REFRACTORY ANEMIA WITH RING SIDEROBLASTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELOPROLIFERATIVE NEOPLASMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELOPROLIFERATIVE NEOPLASMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ESSENTIAL THROMBOCYTHEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ESSENTIAL THROMBOCYTHEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELOFIBROSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELOFIBROSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY POLYCYTHEMIA VERA, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY POLYCYTHEMIA VERA, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELOPROLIFERATIVE NEOPLASMS, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELOPROLIFERATIVE NEOPLASMS, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CAR-T CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CAR-T CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ALLOGENEIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STEM CELL TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STEM CELL TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THALIDOMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THALIDOMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ANTI-CD20, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ANTI-CD20, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ANTI-CD38, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ANTI-CD38, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY BORTEZOMIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CARFILZOMIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY BCR-ABL INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY BCR-ABL INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY BTK INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY BTK INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THERAPY CLASS, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CELLULAR THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CELLULAR THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CAR-T CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CAR-T CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CELLULAR THERAPIES, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CELLULAR THERAPIES, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORY DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORY DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 135. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY POMALIDOMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY POMALIDOMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 137. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THALIDOMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 138. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THALIDOMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 139. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORY DRUGS, 2018-2024 (USD MILLION)
TABLE 140. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORY DRUGS, 2025-2030 (USD MILLION)
TABLE 141. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 142. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 143. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ANTI-CD20, BY REGION, 2018-2024 (USD MILLION)
TABLE 144. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ANTI-CD20, BY REGION, 2025-2030 (USD MILLION)
TABLE 145. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ANTI-CD38, BY REGION, 2018-2024 (USD MILLION)
TABLE 146. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ANTI-CD38, BY REGION, 2025-2030 (USD MILLION)
TABLE 147. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 148. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 149. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 150. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 151. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 152. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY BORTEZOMIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 153. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 154. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CARFILZOMIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 155. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
TABLE 156. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2030 (USD MILLION)
TABLE 157. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 158. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 159. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 160. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 161. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY VENETOCLAX, BY REGION, 2018-2024 (USD MILLION)
TABLE 162. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY VENETOCLAX, BY REGION, 2025-2030 (USD MILLION)
TABLE 163. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 164. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 165. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 166. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 167. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY FIRST-LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 168. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY FIRST-LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 169. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 170. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 171. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SECOND-LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 172. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SECOND-LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 173. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THIRD-LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 174. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THIRD-LINE AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 175. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 176. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 177. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 178. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 179. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 180. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 181. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 182. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 183. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 184. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 185. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 186. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 187. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIRECT PURCHASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 188. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIRECT PURCHASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 189. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 190. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 191. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 192. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 193. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 194. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 195. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 196. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 197. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 198. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 199. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 200. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 201. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 202. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 203. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 204. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 205. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 206. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 207. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 208. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 209. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 210. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HODGKIN LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 211. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 212. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 213. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, 2018-2024 (USD MILLION)
TABLE 214. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, 2025-2030 (USD MILLION)
TABLE 215. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELOPROLIFERATIVE NEOPLASMS, 2018-2024 (USD MILLION)
TABLE 216. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELOPROLIFERATIVE NEOPLASMS, 2025-2030 (USD MILLION)
TABLE 217. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 218. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 219. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 220. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 221. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STEM CELL TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 222. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STEM CELL TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 223. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 224. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 225. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 226. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 227. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 228. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 229. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
TABLE 230. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2030 (USD MILLION)
TABLE 231. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 232. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 233. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
TABLE 234. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THERAPY CLASS, 2025-2030 (USD MILLION)
TABLE 235. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CELLULAR THERAPIES, 2018-2024 (USD MILLION)
TABLE 236. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CELLULAR THERAPIES, 2025-2030 (USD MILLION)
TABLE 237. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORY DRUGS, 2018-2024 (USD MILLION)
TABLE 238. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORY DRUGS, 2025-2030 (USD MILLION)
TABLE 239. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 240. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 241. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
TABLE 242. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2030 (USD MILLION)
TABLE 243. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 244. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 245. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 246. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 247. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 248. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 249. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 250. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 251. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 252. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 253. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 254. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 255. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 256. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 257. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 258. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 259. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 260. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 261. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 262. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HODGKIN LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 263. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 264. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 265. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, 2018-2024 (USD MILLION)
TABLE 266. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, 2025-2030 (USD MILLION)
TABLE 267. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELOPROLIFERATIVE NEOPLASMS, 2018-2024 (USD MILLION)
TABLE 268. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELOPROLIFERATIVE NEOPLASMS, 2025-2030 (USD MILLION)
TABLE 269. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 270. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 271. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 272. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 273. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STEM CELL TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 274. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STEM CELL TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 275. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 276. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 277. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 278. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 279. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 280. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 281. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
TABLE 282. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2030 (USD MILLION)
TABLE 283. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 284. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 285. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
TABLE 286. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THERAPY CLASS, 2025-2030 (USD MILLION)
TABLE 287. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CELLULAR THERAPIES, 2018-2024 (USD MILLION)
TABLE 288. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CELLULAR THERAPIES, 2025-2030 (USD MILLION)
TABLE 289. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORY DRUGS, 2018-2024 (USD MILLION)
TABLE 290. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORY DRUGS, 2025-2030 (USD MILLION)
TABLE 291. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 292. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 293. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
TABLE 294. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2030 (USD MILLION)
TABLE 295. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 296. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 297. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLI

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Hematological Malignancies market report include:
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • AbbVie Inc.
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • Gilead Sciences, Inc.
  • Pfizer Inc.
  • Amgen Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages184
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 18.58 Billion
Forecasted Market Value ( USD ) by 2030 $ 29.76 Billion
Compound Annual Growth Rate9.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Hematological Malignancies - Global Strategic Business Report - Product Image

Hematological Malignancies - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Hematological Disorders Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update - Product Image

Hematological Disorders Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update

  • Report
  • 243 Pages
  • Global
From
Hematologic Malignancies Detection Market Report 2025 - Product Image

Hematologic Malignancies Detection Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Deferiprone - Global Strategic Business Report - Product Image

Deferiprone - Global Strategic Business Report

  • Report
  • 359 Pages
  • Global
From
Disseminated Intravascular Coagulation (DIC) Global Market Report 2025 - Product Image

Disseminated Intravascular Coagulation (DIC) Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From

About the Hematological Malignancies Drug Market

The Hematological Malignancies Drug market is a subset of the pharmaceutical industry that focuses on the development and production of drugs used to treat leukemia and other blood-related cancers. These drugs are used to treat a variety of conditions, including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, and chronic lymphocytic leukemia. The drugs are typically administered intravenously or orally, and may be used in combination with other treatments such as chemotherapy or radiation therapy. The Hematological Malignancies Drug market is highly competitive, with many companies vying for market share. Some of the major players in the market include Novartis, Celgene, Pfizer, Bristol-Myers Squibb, and Merck. Other companies in the market include AbbVie, AstraZeneca, Johnson & Johnson, and Roche. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.